Oct. 30, 2013 In the first molecular genetic study of families with a history of both language impairment and autism, scientists may have uncovered a shared origin for the two conditions, an important step toward explaining why some cases of autism are accompanied by language difficulties and others are not. The study, a collaboration of The Research Institute at Nationwide Children's Hospital with experts at Rutgers University, indicates that a disorder called specific language impairment -- one of the most common developmental delays in children -- may be caused by the same genetic variants that lead to language difficulties in some children with autism. The findings are published Oct. 30 in the American Journal of Psychiatry. As many as two-thirds of individuals with an Autism Spectrum Disorder (ASD) also have language impairments, which can range from mild limitations to complete non-verbal behavior. However, the remaining third may have normal or even above average language abilities. To investigate whether specific language impairment and language-impaired autism cases are caused by the same genetic variants, researchers examined the genetic code of 79 families with a history of both conditions. Using a genome-wide scan and a series of language tests, the researchers identified two … Continue reading →

30 October 2013 Last updated at 14:39 ET By Helen Briggs BBC News Offering genetic testing to lung cancer patients can potentially save lives, research suggests. A study of 5,000 patients found genetic profiling of lung tumours boosted survival rates through better targeting of chemotherapy drugs. The findings, reported in Science Translational Medicine, pave the way for personalised medicine. Cancer Research UK said matching patients to a personalised treatment is still in its infancy. The standard way to diagnose lung cancer is to look at cells from a tumour under the microscope. On this basis, lung cancer can be classified into different tumour types, which helps doctors make decisions about the best treatment to offer. However, in recent years scientists have made progress towards understanding how cancer can be better treated by matching drugs to the genetic make-up of a tumour. A team led by Dr Roman Thomas, of the Max Planck Research Group in Cologne, Germany, carried out genetic testing on lung tumour samples from about 5,000 patients to spot genetic differences in lung cancer cells. Our findings provide support for broad implementation of genome-based diagnosis of lung cancer Continued here: Gene testing raises lung cancer hope … Continue reading →

D'AGE Sheep Placenta Extract / Stem Cell Therapy D'AGE is one of our most precious project, we created the environment and incorporated sand glass into the visual, all the sand effects details was crafted with a lot of TLC. By: ExpressoFX … Continue reading →

Phoenix, Arizona (PRWEB) October 30, 2013 The Arizona Pain Stem Cell Institute is now offering patients the option to avoid surgery for rotator cuff disorders with stem cell injection therapy. There are multiple different types of treatment including bone marrow, fat, or amniotic derived stem cell injections along with PRP therapy. For more information and scheduling, call (602) 507-6550. Millions of individuals suffer from rotator cuff disorders including tendonitis, bursitis and tears. For an unfortunate few, conventional treatments are unable to provide sufficient pain relief. With the advent of regenerative medicine treatments exists the potential for pain relief and increased function without the need for a procedure. At Arizona Pain Stem Cell Institute, Board Certified and Award Winning pain management doctors in Phoenix offer the outpatient treatments which are low risk. The bone marrow and fat are harvested from the patient so there is minimal risk of infection or rejection, while the amniotic derived injections come from consenting donors and processed at an FDA regulated lab. The amniotic injections have been used over 10,000 times world wide without an adverse event. Platelet rich plasma therapy is also provided at the Institute, with published studies showing satisfactory results for pain relief … Continue reading →

Santa Ana, California (PRWEB) October 30, 2013 The top stem cell clinic on the West Coast, Physical First Choice, is now offering stem cell therapy for the nonoperative treatment of rotator cuff disorders. This includes rotator cuff tendonitis, bursitis and tears. Often times, the stem cell injection treatments are able to provide pain relief and return patients back to desired activities. For more information and scheduling, call (888) 988-0515. Millions of individuals in the US suffer from rotator cuff disorders, which can prohibit sports activities and make it difficult to perform any type of overhead activities. An unfortunate few end up requiring surgery for pain relief. With stem cell therapy, operations may not be necessary. Physician First Choice offers bone marrow and fat derived stem cell injections for the shoulder. Both are offered as outpatient, low risk procedures that are performed by the Board Certified doctors at the clinic. The stem cell doctors harvest the fat or bone marrow, which is then immediately processed for injection in the shoulder. Platelet rich plasma therapy is also offered, which only involves a simple blood draw from the patient's arm. PRP therapy has been looked at in small studies and so far the … Continue reading →

PUBLIC RELEASE DATE: 30-Oct-2013 Contact: Jim Ritter jritter@lumc.edu 708-216-2445 Loyola University Health System MAYWOOD, Ill. Performing early stem cell transplants in patients with aggressive non-Hodgkin's lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine. But early transplantation does appear to be beneficial among a small group of patients who are at the very highest risk, the study found. Lead author is Patrick Stiff, MD, director of Loyola University Medical Center's Cardinal Bernardin Cancer Center. The study was developed by the SWOG cancer research cooperative group and funded by the National Cancer Institute. Stiff is chair of the SWOG Bone Marrow and Stem Cell Transplantation Committee. The traditional first-line therapy for aggressive non-Hodgkin's lymphoma is a combination of four chemotherapy drugs. In recent years, physicians have added a fifth drug, the monoclonal antibody rituximab. This five-drug regimen is known as R-CHOP. The treatment typically puts patients into remission. But many patients relapse and go on to get an autologous stem cell transplant after second-line chemotherapy. The study was designed to determine whether doing an early stem cell transplant without first waiting to see whether a patient relapses -- would … Continue reading →

TAMPA The Tampa surgeon who conducted Florida's first heart transplant, a radical procedure at the time, had confidence it would help improve his patients' quality of life. He's pushing ahead with the same confidence in a new arena now only this time, much of the work is being done outside the United States because it's deemed too risky here. Heart patients, again, are among those who stand to benefit from the new procedure boosting and injecting adult stem cells to help repair damaged parts of the body. It works, said the surgeon, Raghavendra Vijaynagar. It is only a start. Perhaps one day stem cells can do much more for someone's heart. Stephen Carre is a believer. The 63-year-old Sun City man had a history of heart problems just walking across the room brought on chest pains and shortness of breath but he didn't rate a top spot on the list of heart transplant candidates. He underwent the new procedure in the Bahamas and now is playing softball again. I felt like a guinea pig, Carre said. But I was desperate, and I trusted Dr. Vijay. The Food and Drug Administration requires more than that, including extensive sanctioned clinical studies to … Continue reading →

ST. PETER Utilizing an innovative new medical procedure, the Nicollet County Sheriff's Office hopes to get a loyal officer back on his feet: Draeco, the 9-year-old German Shepard who serves in the K-9 unit. The Andover Animal Hospital selected five animals this month, including Draeco, to participate in the clinic's first implementation of a new stem cell treatment. Because stem cells treatments are much more effective in animals than humans, the use of stem cells has gained the attention of veterinarians in recent years. The procedure is intended as a safe one-time treatment, though it can repeated if necessary for an animal. It is takes roughly six weeks for the treatment to restore an animal's abilities. Nicollet County Deputy Paul Biederman, the human partner in the K-9 unit, said Draeco has suffered from decreased mobility and endurance in recent years. A K-9 unit typically only serves until the dog is 8 to 10 years old. He said he is hopeful the procedure will improve Draeco's quality of life and extend how long the dog can serve in the department. Few Minnesota veterinary clinics offer the procedure. Unlike the controversial embryonic stem cells, the operation extracts stem cells from the animal's … Continue reading →

PUBLIC RELEASE DATE: 30-Oct-2013 Contact: Jim Ritter jritter@lumc.edu 708-216-2445 Loyola University Health System MAYWOOD, Ill. Performing early stem cell transplants in patients with aggressive non-Hodgkin's lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine. But early transplantation does appear to be beneficial among a small group of patients who are at the very highest risk, the study found. Lead author is Patrick Stiff, MD, director of Loyola University Medical Center's Cardinal Bernardin Cancer Center. The study was developed by the SWOG cancer research cooperative group and funded by the National Cancer Institute. Stiff is chair of the SWOG Bone Marrow and Stem Cell Transplantation Committee. The traditional first-line therapy for aggressive non-Hodgkin's lymphoma is a combination of four chemotherapy drugs. In recent years, physicians have added a fifth drug, the monoclonal antibody rituximab. This five-drug regimen is known as R-CHOP. The treatment typically puts patients into remission. But many patients relapse and go on to get an autologous stem cell transplant after second-line chemotherapy. The study was designed to determine whether doing an early stem cell transplant without first waiting to see whether a patient relapses -- would … Continue reading →